Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 692

1.

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C.

EMBO J. 1999 Jan 15;18(2):363-74.

2.

Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.

Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S.

Princess Takamatsu Symp. 1994;24:162-70. Review.

PMID:
8983073
4.

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N.

J Biol Chem. 2001 Feb 2;276(5):3222-30. Epub 2000 Oct 31.

5.

A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.

Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF.

J Biol Chem. 1999 Dec 3;274(49):34884-92.

6.

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K.

EMBO J. 1996 Jan 15;15(2):290-98. Erratum in: EMBO J. 1996 Apr 1;15(7):1751.

7.
8.
9.

The splice variants of vascular endothelial growth factor (VEGF) and their receptors.

Robinson CJ, Stringer SE.

J Cell Sci. 2001 Mar;114(Pt 5):853-65. Review.

10.
12.

Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro.

Grosskreutz CL, Anand-Apte B, Dupláa C, Quinn TP, Terman BI, Zetter B, D'Amore PA.

Microvasc Res. 1999 Sep;58(2):128-36.

PMID:
10458928
15.

The role of vascular endothelial growth factor in angiogenesis.

Ferrara N, Gerber HP.

Acta Haematol. 2001;106(4):148-56. Review.

PMID:
11815711
16.

Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.

J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85.

17.
18.

A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.

Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M.

Oncogene. 1995 Jan 5;10(1):135-47.

PMID:
7824266
19.

KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.

Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H.

Hepatology. 1999 Nov;30(5):1179-86.

PMID:
10534339
20.

Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells.

Shen BQ, Lee DY, Cortopassi KM, Damico LA, Zioncheck TF.

J Biol Chem. 2001 Feb 16;276(7):5281-6. Epub 2000 Oct 31.

Supplemental Content

Support Center